Patient Controlled Injectors Market Size Set for Explosive Growth, With Projections Indicating $ 12.33 billion by 2031 | The Insight Partners

The report from The Insight Partners lists several stakeholders—including healthcare providers, government agencies and health authorities, insurance providers, and academic and private research organizations—along with valuable insights on how to successfully navigate this evolving market landscape and unlock new opportunities.

NEW YORK, Dec. 13, 2024 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, global patient controlled injectors market is expected to reach US$ 12.33 billion by 2031 from US$ 3.71 billion in 2021; it is anticipated to record a CAGR of 12.9% during the forecast period. Patient controlled injectors are medical devices that allow patients to administer their own medication, typically for pain management, by injecting a pre-measured dose. These devices offer a convenient and controlled administration, particularly in settings such as post-operative care or chronic pain conditions. The patient controlled injectors market is growing owing to the increasing prevalence of chronic diseases, along with the rising demand for personalized medicine. Additionally, the aging population and growing emphasis on home healthcare contribute to the market expansion.

Market leaders and key company profiles          

• Gerresheimer AG
• Johnson and Johnson Services Inc.
• Ypsomed AG
• Westbourne Medical Limited
• Enable Injections
• scPharmaceuticals Inc.
• United Therapeutics Corporation
• BD
• West Pharmaceutical Services Inc.
• Owen Mumford Pharmaceutical Services

Request a Customized Copy of the Patient Controlled Injectors Market Report @ https://www.theinsightpartners.com/reports/patient-controlled-injectors-market/

Overview of Report Findings

Market Segmentation

• Based on product, the patient controlled injectors market is segmented into electronic wearable injectors, mechanical wearable injectors, and infusion pumps. The electronic wearable injectors segment held the largest share of the market in 2021.
• By application, the patient controlled injectors market is categorized into cancer treatment, auto-immune treatment, and blood disorders treatment. The cancer treatment segment accounted for the largest share of the market in 2021.
• In terms of distribution channel, the patient controlled injectors market is segmented into hospital pharmacies, retail pharmacies, and mail order pharmacies. The hospital pharmacies segment led the market in 2021.
• The patient controlled injectors market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Segments Covered –

By Product

• Electronic Wearable Injectors
• Mechanical Wearable Injectors
• Infusion Pumps

By Application

• Cancer Treatment
• Auto-immune Treatment
• Blood Disorders Treatment

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies

Access PDF Sample Patient Controlled Injectors Market Report (Including Graphs, Charts & Figures) – https://www.theinsightpartners.com/sample/TIPRE00015234/

Competitive Strategy and Development

• Trending Topics: Integration of artificial intelligence in patient controlled injectors, patient-centric innovations in home healthcare, the impact of wearable devices on patient controlled injectors technology, sustainability in patient controlled injectors manufacturing, among others.

Global Headlines on Patient Controlled Injectors Market 

• Insulet Acquires Assets of Automated Glucose Control LLC (AGC)
• Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in US.

Regional Analysis –

• The Asia Pacific patient controlled injectors market is expected to reach US$ 1,637.74 million by 2027 from US$ 621.47 million in 2019. The market is anticipated to grow at a CAGR of 12.9% during 2019–2027. The increasing chronic diseases prevalence, and conventional drug delivery system limitations are the major factors expected to boost the growth of the patient controlled injectors market in Asia Pacific.
• The Europe patient controlled injectors market is expected to reach US$ 2,051.31 Mn in 2027 from US$ 835.44 Mn in 2019. The market is anticipated to grow at a CAGR of 12.0% during 2019–2027. The increasing chronic diseases prevalence, and conventional drug delivery system limitations are the major factors expected to boost the growth of the patient controlled injectors market in Europe.
• The North America patient controlled injectors market is expected to reach US$ 3,236.46 million by 2027 from US$ 1,261.43 million in 2019. The market is anticipated to grow at a CAGR of 12.6% during 2019–2027. The increasing chronic diseases prevalence, and conventional drug delivery system limitations are the major factors expected to boost the growth of the patient controlled injectors market in North America.

Get Flat 30% Discount on purchase of Patient Controlled Injectors Market Research Report with 10% extra customization: https://www.theinsightpartners.com/buy/TIPRE00015234/

Conclusion

The patient controlled injectors market is experiencing robust growth, driven by the rising prevalence of chronic diseases, an aging population, and the increasing demand for home healthcare. As patients and healthcare systems shift toward more personalized, at-home treatment options, patient controlled injectors offer a solution that empowers individuals to manage their medication, particularly for pain management, insulin therapy, and other chronic conditions. Technological advancements, such as smart injectors with wireless connectivity and real-time monitoring, are driving the market by improving ease of use, safety, and treatment adherence. Additionally, the global focus on reducing healthcare costs and increasing patient autonomy contributes to the ongoing adoption of these devices. With increased investment in healthcare infrastructure and an emphasis on patient-centric care, the patient controlled injectors market is set to flourish, offering substantial opportunities for growth in both developed and emerging markets in the coming years.

More Trending Latest Research Life Sciences Research Reports by The Insight Partners –

Patient controlled injectors market size in 2021 stood at US$ 3.71 billion and is projected to reach US$ 12.33 billion by 2031 from US$ XX billion in 2023. The market is expected to register a CAGR of 12.9% in 2023–2031

Wearable Injectors Market Forecast, Share, Trends, and Growth 2031

Needleless Injectors Market Size and Forecasts 2021 - 2031

Automatic Injectors Professional Market Size and Forecasts 2021 - 2031

Biologic Injectors Market Size and Forecasts 2021 - 2031

Facial Injectors Market Size and Forecasts 2021 - 2031

Autoinjectors Market Size and Forecasts 2021 - 2031

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person:

Ankit Mathur
E-mail:ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Website - https://www.theinsightpartners.com/
Follow Us: LinkedIn | Facebook | Twitter 

Logo: https://mma.prnewswire.com/media/2520492/The_Insight_Partners_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/patient-controlled-injectors-market-size-set-for-explosive-growth-with-projections-indicating--12-33-billion-by-2031--the-insight-partners-302331378.html

SOURCE The Insight Partners